Search

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Product Type (Corticosteroids, Intravenous immunoglobulins, Anti-D immunoglobulin, Thrombopoietin receptor agonists (TPO-RA)), Treatment Type (Spleenectomy, Oral corticosteroids), Distribution Channel, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-12508
  • Published Date: Oct, 2024
  • Pages: 238
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Global idiopathic thrombocytopenic purpura (ITP) therapeutics market is expected to reach USD 1,065.01 million by 2033, at a CAGR of 5.01% from 2024 to 2033. Global idiopathic thrombocytopenic purpura (ITP) therapeutics market is witnessing a considerable growth owing to increasing demand for the combination therapies for the treatment of idiopathic thrombocytopenic purpura (ITP). 

Market Overview:

Idiopathic thrombocytopenic purpura (ITP) is a common immune disorder caused by platelet-reactive auto antibodies. This is basically an immune disorder, which causes excessive bleeding. The acute type of idiopathic thrombocytopenic purpura (ITP) mainly affects children, whereas as the chronic form affects the adult people.  This disease affects mostly the platelet in the body, which are vital blood cells that help to stop bleeding. A reduction in platelets can result in bleeding gums, easy bruising, and internal bleeding. It is a rare disease as every 100 thousand people, ten people are living with Idiopathic thrombocytopenic purpura. It upsets less than 1% of the world’s people. For some people, ITP can be an ‘invisible disease’ because there may be times where there are no apparent symptoms.

Idiopathic thrombocytopenic purpura (ITP) treatment includes a number of approaches, such as medications to boost the platelet count or surgery to remove the spleen (splenectomy). Children usually improve without treatment. ITP affects approximately four to eight per 100,000 children under the age of 15 each year in the U.S. Most adults with ITP will ultimately essential treatment, as the condition often becomes severe or chronic. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. However, the approval of thrombopoietin-receptor agonists (TPO-RAs), eltrombopag (Promacta) and romiplostim (Nplate), starting in 2008, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment other than immunomodulation.

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers
  • Increasing demand for second and third line therapies

Idiopathic thrombocytopenic purpura (ITP) has various first-line treatment therapies. However, there are instances when first-line treatment does not provide effective results. In such cases, alternative therapies are required to treat the disease, including second- and third-line therapies. These therapies helps to control platelet, prevent bleeding, reduce fatigue, and improve health-related quality of life (HRQoL), which are the significant unmet needs of ITP. Thus, rising demand for the second- and third-line therapies driving the growth of the market. 

  • Rising demand for combination therapies

Increasing demand for the combination therapies for the treatment of idiopathic thrombocytopenic purpura (ITP), is anticipated to boost the market growth in the upcoming years. Combination therapies are significantly efficient for the treatment of idiopathic thrombocytopenic purpura (ITP), as well as these therapies, reduces the overall cost of treatment. Thus, rising demand for these therapies is anticipated to drive the growth of the market over the forecast period.  

Restraints:
  • Side effects of corticosteroids and other drugs could hamper the market growth 

Corticosteroids have been used as the first line of treatment for the ITP from several years. However, there are some side effects of corticosteroids, anticipated to hinder the market growth over the forecast period. Some side effects are such as stopping white blood cells working correctly, which can increase the chances of getting infection, as white blood cells will less able to fight with bacteria and viruses. In addition to this, thinning of bones, increasing blood sugar level, and stomach ulcers are some of the other side effects of long term usage of corticosteroids.

Opportunities:
  • Growing research and development activities for the launch of new drugs 

For decades, treatment options were limited to splenectomy and corticosteroids, followed by the plasma-derived treatments. However, as biology improves, an expanded treatment repertoire is emerging for the ITP disease. Many companies are investing the research and development for the launching novel treatment for ITP. Present research and development activities are mainly focusing on combining therapies to address multiple mechanisms of disease simultaneously.

Challenges:
  • Lack of awareness of the disease among the people

Lack of public awareness can leave many ITP patients untreated, which is expected to hamper the market growth over the forecast period. No facilities for diagnostic test in rural areas and the high cost of treatment in low-income countries, further restraining the growth of the market. 

Segmentation Analysis:

The global idiopathic thrombocytopenic purpura (ITP) therapeutics market has been segmented based on product type, treatment type, distribution channel, and regions.

  • The product type segment is divided into corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, thrombopoietin receptor agonists (TPO-RA), and others. The corticosteroids segment led the idiopathic thrombocytopenic purpura (ITP) therapeutics market with a market share of around 33.81% in 2023. Corticosteroids considered as the slandered initial treatment for adults with immune thrombocytopenic purpura (ITP) because of their effectiveness for increasing the platelet count, their low cost and convenience. They have been used for more than 30 years as a first-line treatment for adult immune thrombocytopenia (ITP). However, Anti-D immunoglobulin is expected to grow at the highest CAGR of 6.8% over the forecast period. The rise in the adoption of anti-D immunoglobulin for the treatment of ITP and considered as a useful option for rapidly increasing platelet counts in patients with symptomatic ITP.
  • The treatment type segment includes spleenectomy and oral corticosteroids. The oral corticosteroids segment held the largest market share of 64.38% in 2023. This is mainly due to it is widely used as first-line therapy for the treatment of idiopathic thrombocytopenic purpura (ITP) for both adults and children.
  • The distribution channel segment includes drug stores, retail pharmacies, and others. The retail pharmacy accounted for the major market share and valued at USD 48.32 % in 2023. This is attributed to the increasing number of trend towards oral therapeutic solutions and procurement of these drugs through retail pharmacies. However, drug stores are anticipated to grow at the highest CAGR, owing to an increase over the counter drugs for the treatment of ITP. 
Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. The North America region emerged as the largest market for the idiopathic thrombocytopenic purpura (ITP) therapeutics market with a 39.85% share of the market revenue in 2023.

The North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share in 2023 - 39.85%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

  • This is because North America is growing tremendously in terms of the healthcare industry. Rising occurrence of diseases coupled with the presence of high treatment rates, and favourable government initiatives, propelling the growth of the market in the North America region. In addition to this, increase in the treatment for the idiopathic thrombocytopenic purpura (ITP) therapeutics and high research and development activities, further driving the growth of the market. 
  • The Asia Pacific region is anticipated to grow at a considerable growth rate in the global idiopathic thrombocytopenic purpura (ITP) therapeutics market, owing to rising healthcare expenditure in the region. Moreover, sophisticated healthcare infrastructure in the countries such as Japan and Australia, fuelling the growth of the market. 
Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global idiopathic thrombocytopenic purpura (ITP) therapeutics industry.

In February 2019, Roche and Spark Therapeutics, Inc. announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics to expand the product portfolio. 

In January 2020, Novartis in association with the ITP Support Association announced the launch of ITP Pocket Log, designed to track symptoms, which is available on Google Play and Apple App Store.

List of Key Market Players:
  • Hoffman-L Roche
  • Novartis
  • GlaxoSmithKline
  • Eisai
  • Amgen
  • GrifolsBiologicals Inc.
  • Baxter
  • CSL Behring
  • Bristol-Myers Squibb,
  • Roxane
Key Target Audience
  • Healthcare Institute
  • Drug Manufacture
  • Pharmaceutical Companies
  • Government Authorities and R&D Institutions
  • World Health Organization
  • Food and Drug Administration
  • Consulting And Research Firm

Report Description:

  • Global Idiopathic Thrombocytopenic Purpura (ITP) therapeutics Market, Industry Analysis, Trends, Analysis and Forecast, 2024 to 2033 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2023 is considered as the base year of the report. 2020, 2021 and 2022 are considered as the historic years and 2024 to 2033 are the forecast years. The global idiopathic thrombocytopenic purpura (ITP) therapeutics market is based on revenue (USD Million/Billion). The report incorporates the market study on the basis of revenue and volume. The study covers the market share revenue/market share for each of the segments, regions and countries catering to global idiopathic thrombocytopenic purpura (ITP) therapeutics market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of idiopathic thrombocytopenic purpura (ITP) therapeutics and regions which are deduced and formulated on the basis of their growth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global idiopathic thrombocytopenic purpura (ITP) therapeutics market. This offers vital and in depth insights in order to depict the overall market scenario.
  • The report offers the detailed study for the company profiles of key organizations operating in the global idiopathic thrombocytopenic purpura (ITP) therapeutics market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development &innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario. 
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
  • Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which act as a key potential for the investors. 
  • Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global idiopathic thrombocytopenic purpura (ITP) therapeutics market is covered in order to comprehend the adoption rate and evaluate the market size.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the idiopathic thrombocytopenic purpura (ITP) therapeutics market was valued at USD 653.20 million in 2023 and is anticipated to reach USD 1,065.01 million by 2033.

Global idiopathic thrombocytopenic purpura (ITP) therapeutics market is growing at a CAGR of 5.01% during the forecast period 2024-2033.

The North America region emerged as the largest market for the idiopathic thrombocytopenic purpura (ITP) therapeutics.

Increasing demand for second and third line therapies is the key driving factor for the idiopathic thrombocytopenic purpura (ITP) therapeutics market.

Side effects of corticosteroids and others drugs could hamper the market growth.

Growing research and development activities for the launch of new drugs will provide huge opportunities to the market.

Key players are Hoffman-L Roche, Novartis, GlaxoSmithKline, Eisai, Amgen, Grifols Biologicals Inc., Baxter, CSL Behring.

Get Your Report Customized

  • Further segmentation of the market on the basis of type, application, end use, product, technology, method, process and any other segment depending on the market
  • Segmentation on the basis of any specific country or region
  • Any segment can be classified on the basis of application
  • Application segment can be further divided on the basis of companies
  • The companies profiled are not limited, we can incorporate additional companies of your choice
  • We can split the company market share on the basis of product, application and region
  • Report can be prepared for any specific country/region/segment
  • Customers can be added on the basis of regions and countries
Request for Customization

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Product Type
          4.3.2. Market Attractiveness Analysis By Treatment Type
          4.3.3. Market Attractiveness Analysis By Distribution Channel
          4.3.4. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing demand for second- and third-line therapies
          5.2.2. Rising demand for combination therapies
    5.3. Restrains
          5.3.1. Side effects of corticosteroids and others drugs
    5.4. Opportunities
          5.4.1. Growing research and development activities for the launch of new drugs
    5.5. Challenges
          5.5.1. Lack of awareness of disease among the people

6. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast, By Product Type
    6.1. Segment Overview
    6.2. Corticosteroids
    6.3. Intravenous immunoglobulins
    6.4. Anti-D immunoglobulin
    6.5. Thrombopoietin receptor agonists (TPO-RA)
    6.6. Others

7. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast, By Treatment Type
    7.1. Segment Overview
    7.2. Spleenectomy
    7.3. Oral Corticosteroids

8. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast, By Distribution Channel
    8.1. Segment Overview
    8.2. Drug Stores
    8.3. Retail Pharmacies
    8.4. Others

9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast, By Regional Analysis
    9.1. Segment Overview
    9.2. North America
          9.2.1. U.S.
          9.2.2. Canada
          9.2.3. Mexico
    9.3. Europe
          9.3.1. Germany
          9.3.2. France
          9.3.3. U.K.
          9.3.4. Italy
          9.3.5. Spain
    9.4. Asia-Pacific
          9.4.1. Japan
          9.4.2. China
          9.4.3. India
    9.5. South America
          9.5.1. Brazil
    9.6. Middle East and Africa
          9.6.1. UAE
          9.6.2. South Africa

10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market-Competitive Landscape
    10.1. Overview
    10.2. Market Share of Key Players in Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
          10.2.1. Global Company Market Share
          10.2.2. North America Company Market Share
          10.2.3. Europe Company Market Share
          10.2.4. APAC Company Market Share
    10.3. Competitive Situations and Trends
          10.3.1. Product Launches and Developments
          10.3.2. Partnerships, Collaborations, and Agreements
          10.3.3. Mergers & Acquisitions
          10.3.4. Expansions

11. Company Profiles
    11.1. Hoffman-L Roche
          11.1.1. Business Overview
          11.1.2. Company Snapshot
          11.1.3. Company Market Share Analysis
          11.1.4. Company Product Portfolio
          11.1.5. Recent Developments
          11.1.6. SWOT Analysis
    11.2. Novartis
          11.2.1. Business Overview
          11.2.2. Company Snapshot
          11.2.3. Company Market Share Analysis
          11.2.4. Company Product Portfolio
          11.2.5. Recent Developments
          11.2.6. SWOT Analysis
    11.3. GlaxoSmithKline
          11.3.1. Business Overview
          11.3.2. Company Snapshot
          11.3.3. Company Market Share Analysis
          11.3.4. Company Product Portfolio
          11.3.5. Recent Developments
          11.3.6. SWOT Analysis
    11.4. Eisai
          11.4.1. Business Overview
          11.4.2. Company Snapshot
          11.4.3. Company Market Share Analysis
          11.4.4. Company Product Portfolio
          11.4.5. Recent Developments
          11.4.6. SWOT Analysis
    11.5. Amgen
          11.5.1. Business Overview
          11.5.2. Company Snapshot
          11.5.3. Company Market Share Analysis
          11.5.4. Company Product Portfolio
          11.5.5. Recent Developments
          11.5.6. SWOT Analysis
    11.6. Grifols Biologicals Inc.
          11.6.1. Business Overview
          11.6.2. Company Snapshot
          11.6.3. Company Market Share Analysis
          11.6.4. Company Product Portfolio
          11.6.5. Recent Developments
          11.6.6. SWOT Analysis
    11.7. Baxter
          11.7.1. Business Overview
          11.7.2. Company Snapshot
          11.7.3. Company Market Share Analysis
          11.7.4. Company Product Portfolio
          11.7.5. Recent Developments
          11.7.6. SWOT Analysis
    11.8. CSL Behring
          11.8.1. Business Overview
          11.8.2. Company Snapshot
          11.8.3. Company Market Share Analysis
          11.8.4. Company Product Portfolio
          11.8.5. Recent Developments
          11.8.6. SWOT Analysis
    11.9. Bristol-Myers Squibb
          11.9.1. Business Overview
          11.9.2. Company Snapshot
          11.9.3. Company Market Share Analysis
          11.9.4. Company Product Portfolio
          11.9.5. Recent Developments
          11.9.6. SWOT Analysis
    11.10. Roxane
          11.10.1. Business Overview
          11.10.2. Company Snapshot
          11.10.3. Company Market Share Analysis
          11.10.4. Company Product Portfolio
          11.10.5. Recent Developments
          11.10.6. SWOT Analysis

List of Table

1. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

2. Global Corticosteroids Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics  Market, By Region, 2020-2033 (USD Million)

3. Global Intravenous immunoglobulins Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics  Market, By Region, 2020-2033 (USD Million)

4. Global Anti-D immunoglobulin Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics  Market, By Region, 2020-2033 (USD Million)

5. Global Thrombopoietin receptor agonists (TPO-RA) Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics  Market, By Region, 2020-2033 (USD Million)

6. Global Others Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics  Market, By Region, 2020-2033 (USD Million)

7. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

8. Global Spleenectomy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Region, 2020-2033 (USD Million)

9. Global Oral Corticosteroids Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Region, 2020-2033 (USD Million)

10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

11. Global Drug Stores Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Region, 2020-2033 (USD Million)

12. Global Retail Pharmacies Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Region, 2020-2033 (USD Million)

13. Global Others Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Region, 2020-2033 (USD Million)

14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Region, 2020-2033 (USD Million) 

15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By North America, 2020-2033 (USD Million)

16. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

17. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

18. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

19. U.S. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

20. U.S. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

21. U.S. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

22. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

23. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

24. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

25. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

26. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

27. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

28. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

29. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

30. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

31. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

32. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

33. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

34. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

35. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

36. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

37. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

38. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

39. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

40. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

41. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

42. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

43. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

44. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

45. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

46. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

47. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

48. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

49. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

50. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

51. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

52. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

53. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

54. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

55. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

56. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

57. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

58. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

59. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

60. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

61. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

62. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

63. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

64. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

65. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

66. Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

67. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

68. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

69. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

70. South Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Product Type, 2020-2033 (USD Million)

71. South Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Treatment Type, 2020-2033 (USD Million)

72. South Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market, By Distribution Channel, 2020-2033 (USD Million)

List of Figures 

1. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Segmentation

2. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Attractiveness Analysis By Product Type

9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Attractiveness Analysis By Treatment Type

10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Attractiveness Analysis By Distribution Channel

11. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Attractiveness Analysis By Region

12. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market: Dynamics

13. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share By Product Type (2023 & 2033)

14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share By Treatment Type (2023 & 2033)

15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share By Distribution Channel (2023 & 2033)

16. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Regions (2023 & 2033)

17. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Company (2023)

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global idiopathic thrombocytopenic purpura (ITP) therapeutics market on the basis of below mentioned segments:

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Product Type:

  • Corticosteroids
  • Intravenous immunoglobulins
  • Anti-D immunoglobulin
  • Thrombopoietin receptor agonists (TPO-RA)
  • Others

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Treatment Type:

  • Spleenectomy
  • Oral Corticosteroids

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Distribution Channel:

  • Drug Stores
  • Retail Pharmacies
  • Others

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Ask for customization Request Sample Speak to analyst Inquire before buying

Flexible Purchase Options

  • Chapters of your choice
  • Quantitative Information for Historical & Forecasted Data
  • Regional/Country Level Reports
Request for Special Pricing

Get in touch with us

+1-315-215-1633

sales@thebrainyinsights.com

Our Clients

Why choose us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date